RVL 1201

Drug Profile

RVL 1201

Alternative Names: RVL-1201

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator RevitaLid
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Blepharoptosis

Most Recent Events

  • 01 Nov 2016 RevitaLid completes a phase III trial for Blepharoptosis in USA (NCT02436759)
  • 04 May 2015 RevitaLid plans a phase III trial for Blepharoptosis in USA (NCT02436759)
  • 01 May 2015 Phase-III clinical trials in Blepharoptosis in USA (Ophthalmic) (NCT02436759)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top